Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc. insiders are currently net buyers of TALS stock, showing bullish sentiment over the past 90 days. Executives have purchased $10.2M while selling $2.7M, resulting in a positive net flow of $7.5M. This buying activity represents 79% of total transaction volume.

Talaris Therapeutics, Inc. has 10 active insiders who have filed SEC Form 4 transactions in the past 90 days. Capital Partners Iii, Llc Longitude (Executive) leads with 2 transactions totaling $4.0M. Sandip Agarwala (Executive) follows with 2 transactions worth $4.0M. Open-market purchases require insiders to invest their own capital, demonstrating genuine conviction.

The Insider Alignment Score measures the ratio of buying to selling activity on a 0-100 scale. Talaris Therapeutics, Inc.'s current score of 79/100 indicates bullish insider sentiment. Scores above 60 suggest insiders are accumulating shares faster than selling, reflecting $10.2M in purchases versus $2.7M in sales.

The most recent insider transaction occurred on Jul 3, 2023, when Requadt Scott (Executive) disposed of 11,786 shares at $3.08 per share for $36.3K. This appears to be a discretionary trade.

Based on SEC Form 4 filings from the past 90 days, TALS insider trading sentiment is currently bullish with an Alignment Score of 79/100. The net insider flow of $7.5M reflects accumulation, with 79% of volume being purchases.

SEC Form 4 is the primary disclosure mechanism for insider trading at publicly traded companies like Talaris Therapeutics, Inc.. Corporate insiders must file within two business days of any transaction, making it one of the most timely sources of executive sentiment. At TALS, we track all Form 4 filings—currently showing 103 transactions from 10 insiders over 90 days.

A 10b5-1 plan allows Talaris Therapeutics, Inc. executives to pre-schedule stock sales when they don't possess material non-public information. At TALS, approximately 42% of recent transactions are 10b5-1 trades. This high percentage suggests much of the selling is routine and pre-planned.

You can monitor Talaris Therapeutics, Inc. (TALS) insider trading activity on this page, which updates within hours of new SEC Form 4 filings. We track all 10 active insiders and provide real-time transaction feeds, the Alignment Score, 10b5-1 vs. discretionary breakdowns, and direct links to SEC EDGAR filings.

Our Alignment Score measures the ratio of insider buying to selling on a scale of 0-100. A score above 70 indicates strong bullish sentiment, while below 30 suggests bearish activity. Talaris Therapeutics, Inc.'s current score of 79/100 indicates strong bullish sentiment with executives accumulating shares. This is calculated from $10.2M in purchases versus $2.7M in sales over 90 days, resulting in a net flow of $7.5M.

SEC Form 4 filings are mandatory reports that Talaris Therapeutics, Inc. insiders must submit within 2 business days. Each filing includes the insider's name, relationship, transaction type, shares, and price. Transaction codes: P (purchase), S (sale), A (award), M (option exercise), G (gift). At TALS, the most common type is "S" with 28 occurrences. The most recent Form 4 was filed on Jul 3, 2023 by Requadt Scott.

Rule 10b5-1 allows corporate insiders to establish pre-scheduled trading plans when they don't possess material non-public information. At Talaris Therapeutics, Inc., approximately 42% of recent transactions are executed under 10b5-1 plans, while 58% appear to be discretionary trades. This mix provides a balanced picture—some planned, others reflecting real-time decisions.